Noninvasive Cardiac Imaging

JENNIFER H. MIERES, M.D., and AMGAD N. MAKARYUS, M.D.,
North Shore University Hospital, North Shore-Long Island Jewish Health System, Manhasset, New York
RITA F. REDBERG, M.D., M.SC., University of California, San Francisco National Center of
Excellence in Women’s Health, San Francisco, California
LESLEE J. SHAW, PH.D., Cedars-Sinai Medical Center, Los Angeles, California

Noninvasive cardiac imaging can be used for the diagnostic and prognostic assessment of patients with suspected or known coronary artery disease. It is central to the treatment of patients with myocardial infarction, coronary artery disease, or acute coronary syndromes with or without angina. Radionuclide cardiac imaging; echocardiography; and, increasingly, cardiac computed tomography and cardiac magnetic resonance imaging techniques play an important role in the diagnosis of coronary artery disease, which is the leading cause of mortality in adults in the United States. Contemporary imaging techniques, with either stress nuclear myocardial perfusion imaging or stress echocardiography, provide a high sensitivity and specificity in the detection and risk assessment of coronary artery disease, and have incremental value over exercise electrocardiography and clinical variables. They also are recommended for patients at intermediate to high pretest likelihood of coronary artery disease based on symptoms and risk factors. Cardiac magnetic resonance imaging and cardiac computed tomography are newly emerging modalities in the evaluation of patients with coronary artery disease. Cardiac magnetic resonance imaging is useful in the assessment of myocardial perfusion and viability, as well as function. It also is considered a first-line tool for the diagnosis of arrhythmogenic right ventricular dysplasia. Cardiac computed tomography detects and quantifies coronary calcium and evaluates the lumen and wall of the coronary artery. It is a clinical tool for the detection of subclinical coronary artery disease in select asymptomatic patients with an intermediate Framingham 10-year risk estimate of 10 to 20 percent. In addition, cardiac computed tomography is evolving as a noninvasive tool for the detection and quantification of coronary artery stenosis. Although guidelines can help with treating patients, treatment ultimately should be tailored to each person based on clinical judgment of the a priori risk of a cardiac event, symptoms, and the cardiac risk profile. (Am Fam Physician 2007;75:1219-28. Copyright © 2007 American Academy of Family Physicians.)
also should be assessed. Based on their Framingham risk score, patients at low risk have a less than 10 percent 10-year CAD risk, patients at intermediate risk have a 10 to 20 percent 10-year CAD risk, and those at high risk have a more than 20 percent 10-year CAD risk. This translates to expected annual rates of CAD death or myocardial infarction (MI) of less than 0.6 percent (low risk), 0.6 percent to 2.0 percent (intermediate risk), and more than 2.0 percent (high risk).8 The online Framingham risk estimate calculator can be found at http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.

Resting 12-lead electrocardiography (ECG) should be performed on all patients with suspected CAD. The presence of left ventricular hypertrophy, ST-segment changes, T-wave changes, diagnostic Q waves in two contiguous leads, and conduction abnormalities (e.g., left bundle branch block) increases the likelihood of CAD.5-10 Noninvasive cardiac testing is recommended for the symptomatic patient at intermediate risk of CAD, based on the presence of risk factors and symptoms.2,4,6,7 Patients who can exercise should undergo treadmill testing alone or in combination with cardiac imaging because this assessment of exercise capacity yields diagnostic and prognostic data.6

Treadmill testing with exercise ECG is the oldest and most commonly used form of noninvasive cardiac testing in the evaluation of patients with suspected CAD. According to the ACC/AHA exercise testing guidelines, patients should undergo exercise treadmill testing if they are at an intermediate pretest risk of CAD based on symptoms and risk factors, have a normal resting ECG, and are capable of maximal exercise.6 Patients with poor functional capacity on treadmill stress testing (less than five metabolic equivalents) typically will have a poor prognosis.3,11,12

In daily clinical practice, the risk assessment helps determine management. Patients with an increased likelihood of a cardiac event should be referred for testing and more intensive treatment, whereas those at low risk of cardiac events can be treated with medical therapy and risk factor modification and avoid further testing.2,10-13,14 Figure 17 is an algorithm showing the diagnosis and risk stratification of patients with suspected CAD; it is based on ACC/AHA guidelines for the evaluation of stable angina.

Cardiac Radionuclide Imaging: SPECT Myocardial Perfusion Imaging

UTILITY AND PATIENT SELECTION

Stress myocardial perfusion imaging with single-photon emission computed tomography (SPECT) uses radioactive tracers to provide information about regional blood flow, coronary artery perfusion, and ventricular function.2 A meta-analysis of 33 studies, which included thallium 201 and technetium tracers, found that nuclear exercise stress imaging for the detection of CAD (50 percent or more stenosis) had an average sensitivity of 87 percent and specificity of 73 percent.2 Pharmacologic stress SPECT myocardial perfusion imaging with vasodilator agents (e.g., adenosine [Adenoscan] and dipyridamole [Persantine]) is often used and has a high diagnostic accuracy in patients with suspected CAD who are incapable of
exercise. The overall estimated sensitivity of vasodilator stress is 89 percent with a specificity of 75 percent.\(^2\) Vasodilator pharmacologic SPECT has been shown to be more accurate than exercise perfusion imaging in the identification of CAD in patients with a left bundle branch block.

Over the last decade, innovations in myocardial perfusion imaging have resulted in substantial improvements in its accuracy. The lower energy-isotope (thallium 201) is now largely supplanted by the use of technetium–based imaging agents that improve accuracy, particularly with ECG gated SPECT imaging.\(^2\) With ECG gated SPECT, image data are acquired in synchrony with the ECG signal, facilitating the evaluation of wall motion and ejection fraction. Recent clinical studies have suggested that technetium agents have better specificity, especially for women with suspected CAD in whom false-positive results caused by breast attenuation and small left ventricular chamber size were common with the use of thallium 201.\(^3,15\)\(^-\)\(^17\)

Within the last three years, the validation and addition of attenuation correction techniques to myocardial perfusion imaging have demonstrated improved specificity.\(^2\)
Overall, in patients with symptoms suggestive of typical or atypical angina, exercise or pharmacologic stress SPECT myocardial perfusion imaging yields a sensitivity for detecting CAD of 85 to 90 percent and a specificity of 80 to 90 percent when gated SPECT is used.\textsuperscript{2,15-17}

Myocardial perfusion imaging has been shown to have powerful predictive value for the development of subsequent cardiac death or MI or the need for coronary revascularization. Stress myocardial perfusion imaging provides prognostic information supplemental to that of clinical and exercise ECG variables, and has an excellent negative predictive value for identifying patients at low risk of cardiac events (e.g., death, MI).\textsuperscript{2} A normal perfusion scan at peak stress is associated with an excellent outcome and a cardiac event rate of less than 1 percent per year. Prognosis worsens relative to the number of vascular territories involved, the extent and severity of defect size, and the degree of reversibility. Additional negative prognostic components include poststress ejection fraction less than 45 percent, end-systolic volume more than 70 mL, transient ischemic dilation, and increased lung uptake of thallium 201.\textsuperscript{2,18-22}

Recent validations of contemporary computer techniques and protocols have resulted in decreased radiation exposure and shorter imaging times.\textsuperscript{2,23,24}

**RECOMMENDATIONS FOR CARDIAC RADIUOINUCLE IDE STRESS TESTING**

Table 1\textsuperscript{2-4,6} lists the guidelines for cardiac radionuclide stress testing. The guidelines are based on evidence or general agreement that a given procedure is useful and effective.

**Echocardiography and Stress Echocardiography**

**UTILITY AND PATIENT SELECTION**

Two-dimensional echocardiography provides excellent images of the heart and great vessels, as well as the assessment of regional and global left and right ventricular function. Of all the noninvasive techniques, it is the most versatile and provides the most ancillary information at the lowest cost.\textsuperscript{4} Stress echocardiography with exercise or dobutamine (Dobutrex) can assess for the presence of left ventricular systolic or diastolic dysfunction, valvular heart disease, and the extent of infarction and stress-induced ischemia. Exercise echocardiography may be performed using treadmill, supine bicycle, or upright bicycle. In patients who cannot exercise, dobutamine is the most commonly used pharmacologic stress agent; vasodilator stress echocardiography (with dipyridamole or adenosine) has been reported to have a lower diagnostic sensitivity for single vessel disease.\textsuperscript{23} Transient regional wall motion abnormality, if visualized in the setting of exercise or dobutamine stress, is a marker of CAD.

Based on data in patients with suspected CAD, stress echocardiography has demonstrated very good diagnostic accuracy for detecting or excluding significant CAD, with a mean sensitivity of 81 percent, a specificity of 86 percent, and overall accuracy of 84 percent.\textsuperscript{25,26} In patients with suspected CAD who cannot exercise, dobutamine stress echocardiography reliably detects multivessel stenoses with sensitivities in the range of 75 to 93 percent and specificities in the range of 79 to 92 percent.\textsuperscript{4}

In patients with chronic CAD, left ventricular ejection fraction (LVEF) measured at rest has an important

<table>
<thead>
<tr>
<th>Table 1. Recommended Uses for Cardiac Radionuclide Stress Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment)</td>
</tr>
<tr>
<td>In patients with suspected acute coronary syndrome in the emergency department with nondiagnostic ECG and initial biomarkers</td>
</tr>
<tr>
<td>Diagnosis of chronic CAD relating to the diagnosis of symptomatic and select asymptomatic patients with myocardial ischemia; assessment of ventricular performance; identification of lesions causing myocardial ischemia before planning percutaneous intervention; and risk stratification before noncardiac surgery in select patients</td>
</tr>
<tr>
<td>Diagnosis, prognosis, and therapy assessment in patients with unstable angina or non-ST-elevation MI; identification of ischemia in the distribution of the culprit lesion or in remote areas; measurement of baseline left ventricular function; and identification of disease severity in patients whose angina is satisfactorily stabilized with medical therapy</td>
</tr>
<tr>
<td>Prognosis and risk and therapy assessment after ST-elevation acute MI; assessment of resting right ventricular and left ventricular function; assessment of the presence or extent of stress-induced ischemia; and detection of infarct size and residual viable myocardium</td>
</tr>
<tr>
<td>Assessment of interventions in chronic CAD for the presence of restenosis after coronary intervention</td>
</tr>
<tr>
<td>Determination of initial left ventricular and right ventricular performance in heart failure; initial evaluation of left ventricular function in patients receiving chemotherapy with doxorubicin (Adriamycin); and assessment of myocardial viability in patients with CAD and left ventricular dysfunction without angina</td>
</tr>
</tbody>
</table>

\textsuperscript{CAD = coronary artery disease; ECG = electrocardiography; MI = myocardial infarction. Information from references 2 through 4, and reference 6.}
Electron beam tomography is established as a powerful means of detecting obstructive coronary disease. 32 When calcium scores are high (over 400) or moderate (101 to 400), there is a greater prevalence of obstructive coronary disease. 32,33,38,39,40 Higher scores are associated with a higher relative risk of CAD events (RR, 4.3 to 17.0; 95% CI, 3.1 to 34.0). 33 Despite heterogeneity in some studies, the coronary artery calcium score appears to be an independent predictor of CAD events. 32-34 More recent studies of coronary artery calcium further suggest that these scores predict CAD events; however, the amount of coronary artery calcium does not correlate with the focal stenosis severity of a given lesion. 34,35 Therefore, the use of calcium scanning for predicting the necessity of performing angioplasty or bypass surgery is limited. 33,34,40-44

In addition to the quantification of calcium, a new generation of multislice CT scanners permits the noninvasive acquisition of very high-quality coronary CT angiography. According to a study that evaluated 103 consecutive patients, early generation cardiac CT using 16-slice multidetector CT still performed quite well. When compared with invasive coronary angiography, multidetector CT had a high discriminative power.

A recent meta-analysis found that even low coronary artery calcium scores (1 to 100) are associated with about twice the risk of CAD events compared with those persons who have no evidence of coronary artery calcium (a summary adjusted relative risk [RR] of 2.1; 95% confidence interval [CI], 1.6 to 2.9). 33 Higher scores are associated with a higher relative risk of CAD events (RR, 4.3 to 17.0; 95% CI, 3.1 to 34.0). 33 Despite heterogeneity in some studies, the coronary artery calcium score appears to be an independent predictor of CAD events. 32-34

RECOMMENDATIONS FOR ECHOCARDIOGRAPHY AND STRESS ECHOCARDIOGRAPHY

Table 2 lists the guidelines for echocardiography in the diagnosis of CAD. These guidelines are based on evidence or general agreement that a given procedure is useful and effective.

Cardiac CT: Coronary Calcium Scoring and Noninvasive Coronary Angiography

Utility and Patient Selection

Cardiac CT detects and quantifies the amount of coronary artery calcium (a marker of CAD burden) using either electron beam tomography or multidetector CT. Coronary artery calcium scores approximate the total atherosclerotic plaque burden and strongly predict future cardiac events. 32 In patients with moderate (101 to 400) or higher (over 400) calcium scores, there is a greater prevalence of obstructive coronary disease. 32-34

Electron beam tomography is established as first-line testing for the detection of coronary artery calcium.

Table 2. Recommended Uses for Echocardiography and Stress Echocardiography

| Diagnosis of underlying cardiac disease in patients with chest pain and clinical evidence of valvular, pericardial, or primary myocardial disease |
| Assessment of left ventricular function (when needed) to guide institution and modification of drug therapy in patients with known or suspected left ventricular dysfunction |
| Evaluation of chest pain in patients with suspected acute myocardial ischemia when baseline ECG is nondiagnostic and when study can be obtained during pain or soon after its abatement |
| Evaluation of chest pain in patients with suspected aortic dissection |
| Diagnosis of suspected acute ischemia or infarction not evident by standard means |
| Assessment of functional significance of coronary lesions (if not already known) in planning percutaneous transluminal coronary angioplasty |
| Assessment of infarct size or extent of jeopardized myocardium |
| Stress echocardiography is recommended in patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment) |

ECG = electrocardiography; CAD = coronary artery disease.

Information from reference 4.
to detect significant obstructive CAD, with sensitivity and specificity in the 90 percent range. Multidetector CT does have limitations, including high radiation exposure, the need to administer contrast media, and the need to obtain a heart rate of 60 beats per minute or less; however, a recent study found that 64-slice multidetector CT had a sensitivity for the detection of stenosis of more than 75 percent and a specificity of 97 percent.

**RECOMMENDATIONS FOR CARDIAC CT**

Cardiac CT has been demonstrated to provide quantitative measures of calcified and noncalcified coronary artery plaque. Calcified coronary plaque, as determined by cardiac CT, documents the presence of coronary atherosclerosis and identifies persons at elevated risk of MI and cardiovascular death. Although a positive calcium scan indicates CAD, often there is no significant stenosis. Therefore, the recent AHA expert consensus document on the assessment of CAD by cardiac CT notes the lack of supportive evidence for the widespread screening for CAD and instead endorses the use of calcium testing as a screening procedure in select groups of patients.

A number of studies have reported that coronary artery calcium has independent and incremental value when added to clinical or historical data in the estimation of death and nonfatal MI.

Recent expert consensus documents have suggested using calcium scoring in clinically selected, asymptomatic patients with an intermediate Framingham 10-year risk estimate of 10 to 20 percent (Figure 2).

In addition, the assessment of coronary calcium may be reasonable in the evaluation of symptomatic patients in the setting of an equivocal stress test. The guidelines note that the use of multidetector CT for the noninvasive assessment of lumen coronary artery stenosis in specific circumstances and in specific symptomatic patients is being evaluated and has the potential to change the current diagnostic and management algorithms. Based on the current body of evidence, recent appropriateness criteria have been published to guide patient selection for cardiac CT and cardiac MRI.

**Cardiac MRI**

**UTILITY AND PATIENT SELECTION**

Cardiac MRI is a noninvasive technique for evaluating right and left ventricular function, cardiac masses, and congenital heart disease, and for identifying patients with suspected arrhythmogenic right ventricular dysplasia. Cardiac MRI angiography is a standard technique for imaging the aorta and large vessels of the chest and abdomen, as well as assessing the anomalous origin and course of coronary arteries. Cardiac MRI evaluates the presence of CAD by multiple techniques including direct visualization of coronary stenoses; determination of flow within the coronary arteries; evaluation of myocardial perfusion and metabolism; assessment of abnormal wall motion during stress; and identification of infarcted myocardium as well as viable myocardium using delayed hyperenhancement imaging.

New techniques with cardiac MRI perfusion imaging have demonstrated ability to detect high-grade coronary artery stenoses and to characterize the severity of valvular disease.

The use of cardiac MRI in the risk assessment and prognostication of patients with suspected and known CAD was recently evaluated in a study of 279 patients who were referred for dobutamine-atropine cardiac MRI. The presence of inducible ischemia or an LVEF of less than 40 percent were predictors of CAD, death, or MI at an average follow-up of 20 months. Patients who had no evidence of ischemia and who had an LVEF of 40 percent or more had an excellent prognosis in the two years following stress cardiac MRI.

**RECOMMENDATIONS FOR CARDIAC MRI**

Studies suggest that cardiac MRI is clinically useful in the assessment of myocardial viability and the evaluation of cardiac structure and function. Recent data demonstrate an evolving role of cardiac MRI in the diagnosis and risk assessment of patients with known or suspected CAD; however, there are limited data to support its use in this setting.

**Conclusion**

Based on a growing body of evidence, cardiac imaging using contemporary techniques of stress echocardiography or ECG gated SPECT myocardial perfusion imaging provides accurate diagnostic and prognostic information for persons with suspected CAD. Local expertise and availability should guide technique selection.

Research continues to improve existing techniques and applications in the areas of cardiac CT and cardiac MRI. Definitive randomized clinical trial data are not yet available; however, based on existing evidence, many experts advocate that asymptomatic men and women with significant subclinical coronary atherosclerosis should be treated to secondary prevention goals. The asymptomatic patient with a calcium score over 400 has an annual 2 percent risk of CAD death or MI and should be considered at high cardiac risk. Figure 2 is an algorithm that expands the current clinical guidelines.
for diagnosis and risk assessment of patients with suspected CAD to include the evaluation of asymptomatic patients at intermediate to high risk. A review of the current data suggests that patients with suspected CAD can be accurately diagnosed and risk stratified using contemporary cardiac imaging techniques.

This article is one in a series developed in collaboration with the American Heart Association. Guest editor of the series is Sidney C. Smith, Jr., M.D., Chief Science Officer, American Heart Association, Dallas, Tex. The series coordinator for AFP is Sumi Sexton, M.D.

**The Authors**

JENNIFER H. MIERES, M.D., F.A.C.P., F.A.C.C., is currently the director of nuclear cardiology and an associate professor of medicine at New York University School of Medicine in New York, N.Y. At the time of writing this manuscript, Dr. Mieres was director of nuclear cardiology in the Division of Cardiology at North Shore University Hospital, North Shore-Long Island Jewish Health System in Manhasset, N.Y. She received her medical degree from the Boston (Mass.) University School of Medicine and completed an internal medicine residency and a cardiology fellowship at St. Luke’s Roosevelt Hospital Center in New York, N.Y.

---

**Testing of Patients at Risk of CAD**

**Asymptomatic screening for subclinical disease**

- Intermediate to high-risk, asymptomatic patient with a Framingham 10-year CAD risk estimate of 10 to 20 percent or higher

- Consider screening
  - Commonly applied measures of subclinical disease:
    - Ankle-brachial index
    - Carotid intimal-medial thickness
    - Retinography
    - CT coronary calcium

- High risk

- Evaluate ischemic burden

- **A** Stress testing
  - ECG
  - Echocardiography
  - SPECT
  - Cardiac MRI*

- High-risk study

- Return to **B**

- Low-risk study

**Detection of obstructive CAD: evaluation of ischemic burden for risk assessment**

- Symptom onset

- High risk

- Intermediate risk
  - Go to **A**

- Low risk

- No testing

- **B** Consider cardiac catheterization, anti-ischemic therapy, and risk factor modification

**Figure 2.** Algorithm for testing of asymptomatic and symptomatic patients at risk of coronary artery disease (CAD), including detection of subclinical and obstructive coronary disease. (CT = computed tomography; ECG = electrocardiography; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.)

AMGAD N. MAKARYUS, M.D., is currently an advanced fourth-year cardiovascular imaging fellow at Columbia-Presbyterian Medical Center in New York, N.Y. At the time of writing this manuscript, Dr. Makaryus was a third-year cardiology fellow at North Shore University Hospital, North Shore-Long Island Jewish Health System. He received his medical degree from the State University of New York at Brooklyn College of Medicine and completed an internal medicine residency and a cardiology fellowship at the Columbia-Presbyterian Medical Center and a noninvasive cardiology fellowship at Mt. Sinai Medical Center in New York, N.Y.

LESLEE J. SHAW, PH.D., is the director of outcomes research and a professor of medicine at Emory University School of Medicine in Atlanta, Ga. At the time of writing this manuscript, Dr. Shaw was the director of outcomes research at Cedars-Sinai Medical Center in Los Angeles, Calif. She received her Ph.D. from St. Louis (Mo.) University and completed a clinical research fellowship at Duke University Medical School in Durham, N.C.

Address correspondence to Jennifer H. Mieres, M.D., Director of Nuclear Cardiology, New York University School of Medicine, 550 First Ave., TCH-2 Room HW 246, New York, NY (e-mail: Jennifer.mieres@med.nyu.edu). Reprints are not available from the authors.

Author disclosure: Dr. Mieres has received research and grant support from General Electric Healthcare and is on the speaker’s bureau for Astellas Pharma USA, Inc.

Dr. Makaryus has nothing to disclose.

Dr. Redberg has received research and grant support from the Robert Wood Johnson Foundation and The Flight Attendant Medical Research Institute.

Dr. Shaw has received grant support from BMS-Medical Imaging, General Electric Healthcare, Astellas Pharma USA, Inc., and King Pharmaceuticals, and is on the speaker’s bureau for Astellas Pharma USA, Inc.

REFERENCES


